Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3

By sjmartinez • December 5, 2022

Rugo HS, Im SA, Joy AA, Shparyk Y, Walshe JM, Sleckman B, Loi S, Theall KP, Kim S, Huang X, Bananis E, Mahtani R, Finn RS, Diéras V. Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3. Breast. 2022 Nov 15;66:324-331. doi: 10.1016/j.breast.2022.11.005. Epub ahead of print. PMID: 36463643.

Tags: Advanced breast cancer, chemotherapy, Digestive Diseases, Hematology/Oncology, Palbociclib, Progression-free survival, Publications, safety

Surviving the Odds: Primary Cardiac Lymphoma With Locoregional Lymph Node Involvement Complicated by Pericardial Effusion and Arrhythmia

Bachour K, Shah S, Reichl A, Chia J, Shabsovich DS, Castillo A, Cho G. Surviving the Odds: Primary Cardiac Lymphoma With Locoregional Lymph Node Involvement[...]

Development and Validation of Crohn’s Perianal Fistula Educational Videos and Website for Increasing Patient Knowledge and Engagement

Khalil C, Mehra M, Yang Y, Choi SY, Ballesteros J, Krut Z, Bonthala N, Zaghiyan K, Gu P, Yeo YH, Spiegel BMR, Almario CV. Development[...]

Expanding the menu of dietary therapies in irritable bowel syndrome

Shin A. Expanding the menu of dietary therapies in irritable bowel syndrome. Lancet Gastroenterol Hepatol. 2025 Apr 18:S2468-1253(25)00070-6. doi: 10.1016/S2468-1253(25)00070-6. Epub ahead of print. PMID:[...]